Professional
Added to YB: 2024-11-26
Pitch date: 2024-11-11
REGN [bullish]
Regeneron Pharmaceuticals, Inc.
-8.19%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Market Cap
$77.2B
Pitch Price
$819.76
Price Target
1.0K (+35%)
Dividend
0.47%
EV/EBITDA
13.96
P/E
18.09
EV/Sales
4.30
Sector
Biotechnology
Category
growth
Show full summary:
Regeneron Pharmaceuticals, Inc.: BUY on recent Dupixent approvals, pipeline progress
REGN: BUY at $1000 PT. Recent approvals for Dupixent (EoE, COPD, CRSwNP), Ordspono in EU for R/R FL & DLBCL. Positive data for Eylea HD, Libtayo. 3Q rev +11%, EPS +8%. Pipeline progress, new indications. Undervalued at 18x 2024E EPS vs peers. $18.29B cash, 8% debt/cap. 21% upside potential.
Read full article (9 min)